ClinicalTrials.gg
Active, not recruitingNCT03284502Updated Aug 1, 2023

HM95573 in Combination With Either Cobimetinib or Cetuximab in Patients With Locally Advanced or Metastatic Solid Tumors

A Phase 1 interventional study of HM95573, cobimetinib and HM95573, cetuximab in Locally Advanced Solid Tumor and Metastatic Solid Tumor, sponsored by Hanmi Pharmaceutical Company Limited. Active, not recruiting at 9 sites in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2023-08-01.

Sponsored by Hanmi Pharmaceutical Company Limited · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Sep 2024, 2 years 1 month ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
148
Allocation
Non-randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 269 studies in Neoplasm Metastasis with a site in Korea, Republic of — 58 open to participants now, 107 under way, 35 of them phase 3. Neoplasm Metastasis · Korea, Republic of.

Enrollment
150th of 256
148 · median 200
Started
2017
with 10 others
Phase 1
51 of 269
16 open now
Primary completion
2024-09
later than 12 of 106 live
Registered
118th of 269
by date

Among the 269 studies in Neoplasm Metastasis with a site in Korea, Republic of, this one is the 150th largest by enrollment of the 256 interventional ones that give a count, is one of 11 that started in 2017, is one of 51 in phase 1, reaches primary completion later than 12 of the 106 other live ones, and was the 118th registered.

Neoplasm Metastasis

4,046 studies on the registry are indexed under Neoplasm Metastasis; 888 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

58 of the 269 studies in Neoplasm Metastasis with a site in Korea, Republic of are open now. Recruiting first, the newest first:

53 more — sign in →

All 58 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 689 Neoplasm Metastasis studies recruiting now, 536 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 269 studies in Neoplasm Metastasis with a site in Korea, Republic of, or all of them as a file.
02

Study summary

This study evaluates the safety, tolerability and pharmacokinetics of HM95573 In combination with either cobimetinib or cetuximab in patients with locally advanced or metastatic solid tumors.

Read the detailed description

This is a Phase Ib, open-label, multicenter dose-escalation study designed to assess the safety, tolerability, and pharmacokinetics of oral dosing of HM95573 in combination with either cobimetinib or cetuximab in patients with histologically/cytologically confirmed, locally advanced, or metastatic solid tumors with RAS- or RAF-mutation for which standard therapies either do not exist or have proven ineffective or intolerable. Treatment will continue until disease progression, unacceptable toxicity, any other discontinuation criterion is met.

There are two stages of this study: Stage 1 and 1b, standard 3+3 dose escalation, and Stage 2, an indication-specific dose expansion. Stage 1 is designed to establish the combination MTD for cobimetinib and HM95573. Stage 1 consists of concurrent administration of cobimetinib and HM95573. Stage 1b, is designed to select the combination dose of cetuximab and HM95573 for expansion stage.

In Stage 2 expansion cohort I and II, the RD of cobimetinib and HM95573 with different dosing schedules or regimens might be investigated (which may be≤ MTDs established during dose escalation) in indication-specific expansion cohorts. Stage 2 expansion cohort III will further characterize the safety and tolerability of cetuximab in combination with HM95573.

03

Conditions studied

  • Locally Advanced Solid Tumor
  • Metastatic Solid Tumor

Browse trials for

Keywords

  • Belvarafenib
  • HM95573
  • GDC-5573
  • RG6185
  • Cobimetinib
  • Cetuximab
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

[Inclusion criteria]

  1. Signed Form
  2. Age ≥ 19 years at time of signing Informed Consent Form
  3. performance status of 0 or 1
  4. or cytologically documented, locally advanced or solid tumors with RAS- or RAF-mutation for which standard therapy either does not exist or has proven ineffective or intolerable
  5. per v1.1
  6. ≥ 12 weeks
  7. Adequate hematologic and end organ function, defined by the following laboratory results obtained within 2 weeks prior to the first dose of study-drug treatment: ≥ 1,500/μL count ≥ 100,000/μL ≥ 9.0 g/dL (this criterion has to be met without transfusion within 2 weeks prior to laboratory test) Albumin ≥ 2.5 g/dL Total ≤ 1.5 × or ALT ≤ 3 × ULN, ALP ≤ 2.5 × ULN, with the following exceptions:

    • Patients with documented liver metastases: AST and/or ALT ≤ 5 × ULN
    • Patients with documented liver or bone metastases:

    ALP ≤ 5 × ULN Serum creatinine ≤ 1.5 × ULN, or ≥ 50 mL/min on the basis of the Cockroft-Gault estimation and PTT ≤ 1.5 × ULN

  8. For female patients of and male patients with partners of childbearing potential, agreement (by patient and/or partner) to use one highly effective form (defined as a failure rate of less than 1% per year) of (e.g., surgical sterilization, birth control pills, or contraceptive hormone implants) and to continue use for the duration of the study. Additionally, female patients of childbearing potential should use pregnancy prevention measures for a minimum of 3 months following discontinuation of HM95573 in combination with either cobimetinib or cetuximab.
  9. For male patients: agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom, and agreement to refrain from donating sperm, as defined below: For men with female partners of childbearing potential or pregnant female partners, men must remain abstinent or use a condom during the treatment period and for 3 months after the last dose of HM95573 in combination with either cobimetinib or cetuximab to avoid exposing the embryo. Men must refrain from donating sperm during this same period. The length of time that pregnancy preventative measures are used following discontinuation of drug may be adjusted based on the human pharmacokinetics.
  10. Consent to provide (either a paraffin-embedded tissue block or unstained slides) for testing with the FoundationOne panel to assess and confirm genetic alterations including, but not limited to, KRAS, NRAS, BRAF, EGFR and PI3K mutational status.
  11. FDG-PET avid disease on baseline scan. Patients who are considered for enrollment into the cohort expansion (Stage 2) must meet all of the following additional eligibility criteria:
  12. No more than five prior systemic therapies for locally advanced or metastatic cancer
  13. For the expansion cohorts (except basket cohort in expansion cohort I, II): No prior therapy with a RAF, MEK or ERK inhibitor. No prior treatment with regorafenib in the CRC (KRAS G13D- and BRAF V600-mutant) expansion cohort II. No prior therapy with HM95573 or cobimetinib in the expansion cohort II. For Stage 1b and the expansion cohort III prior EGFR, RAF, MEK, ERK inhibitor is allowed.
  14. Current cancer must be one of the following:

    • Expansion cohort I (HM95573 200 mg BID + cobimetinib 20 mg QD):

      • KRAS-mutant NSCLC
      • KRAS-mutant Pancreatic adenocarcinoma
      • RAS-mutant CRC
      • RAS- or RAF-mutant solid tumors (basket cohort; excludes KRAS-mutant NSCLC, KRAS-mutant pancreatic adenocarcinoma, and RAS-mutant CRC). A minimum of 10 melanoma patients will be enrolled.
    • Expansion cohort II (HM95573 300 mg BID + cobimetinib 20mg QOD (3 times a week: day 1, 3, 5, 8, 10, 12, 15, 17, 19 of 28 day cycle)):

      • KRAS G13D-mutant CRC
      • BRAF V600-mutant CRC
      • NRAS-mutant Melanoma
      • RAS- or RAF-mutant solid tumors (basket cohort: A minimum of 10 BRAF V600 melanoma will be enrolled)
      • BRAF Class II-mutant (including BRAF fusions) or Class IIImutant solid tumors
    • Stage 1b and Expansion cohort III (HM95573 selected dose from stage 1b + cetuximab): - BRAF V600-mutant CRC
  15. At least one target lesion on CT must also be an FDG-PET avid region of interest which has a target-to-organ-background SUVmax (or similar radioactivity concentration measure) ratio of ≥ 2.0 and at least 15mm in longest diameter.
  16. Consent to undergo pre- and post-treatment tumor biopsies for PD biomarker analysis is optional, provided sites of disease are easily and safely accessible. In the absence of easily and safely accessible sites of disease, patients may enroll without consenting to tumor biopsies (Stage 2).
  17. Willingness to take prophylactic antibiotics and topical for the management of skin toxicity unless otherwise for patient in Stage 1b and Expansion cohort III.

[Exclusion criteria]

Patients who meet any of the following criteria will be excluded from study entry:

  1. History of prior significant toxicity from another RAF, MEK, ERK, or EGFR inhibitor requiring discontinuation of treatment
  2. History of or evidence of retinal pathology on ophthalmologic examination that is considered a risk factor for central serous retinopathy, retinal vein occlusion (RVO), or neovascular macular degeneration. Patients will be excluded from study participation if they currently are known to have any of the following risk factors for RVO:

    • Grade ≥ 2 or symptomatic hyperglycemia (fasting)
    • Grade ≥ 2 uncontrolled hypertension (patients with a history of hypertension controlled with anti-hypertensive medication to Grade ≤ 1 are eligible)
  3. History of glaucoma
  4. Allergy or to components of the cobimetinib, cetuximab or HM95573 formulation
  5. Palliative radiotherapy within 2 weeks prior to first dose of study-drug treatment in Cycle 1
  6. Experimental therapy within 4 weeks prior to first dose of study-drug treatment in Cycle 1
  7. Major surgical procedure or significant traumatic injury within 4 weeks prior to the first dose of study-drug treatment in Cycle 1, or anticipation of the need for major surgery during the course of study treatment
  8. Anti-cancer therapy within 28 days prior to the first dose of study-drug treatment in Cycle 1. Exceptions include a of at least five half-lives for anti-PD1 or anti-PDL1 antibodies and ipilimumab during Stage I dose escalation and at least three halflives for anti-PD1 or anti-PDL1 antibodies and ipilimumab during Stage II expansion phase, a washout of 6 weeks for nitrosoureas or mitomycin C, or 14 days for hormonal therapy or kinase inhibitors. (upon discussion with the Medical Monitor, fewer than stated wash-out period may be allowed provided that the patient has adequately recovered from any toxicity).
  9. Current Grade > 1 toxicity (except alopecia and anorexia) from prior therapy or Grade > 1 neuropathy from any cause
  10. Current severe, uncontrolled systemic disease (including, but not limited to, clinically significant cardiovascular, pulmonary, or renal disease, ongoing or active infection)
  11. History of clinically significant cardiac dysfunction, including the following: Current uncontrolled Grade ≥ 2 hypertension or unstable angina
  12. History of symptomatic congestive heart failure of class III or IV or serious cardiac arrhythmia requiring treatment, with the exceptions of atrial fibrillation and paroxysmal supraventricular tachycardia
  13. History of myocardial infarction within 6 months prior to the first dose of study-drug treatment in Cycle 1
  14. History of bradyarrhythmias, bradycardia or heart block or baseline HR \< 55bpm
  15. History of congenital long syndrome or QTcF > 440 msec
  16. (as measured by echocardiography [ECHO] or multi-plegated acquisition scan [MUGA]) \< 50% or below the lower limit of normal (LLN; whichever is lower)
  17. Inability or unwillingness to swallow pills
  18. History of malabsorption or other condition that would interfere with enteral absorption
  19. Clinically significant history of liver disease (including cirrhosis), current alcohol abuse, or current known active infection with , virus, or virus
  20. Any hemorrhage or bleeding event Grade 3 or higher within 28 days of Cycle 1, Day 1
  21. Patients receiving therapeutic anticoagulation or thrombolytic anticoagulants. Use of low molecular weight heparin and low dose aspirin are allowed.
  22. Active disease
  23. Uncontrolled ascites requiring weekly large volume paracentesis for 3 consecutive weeks prior to enrollment
  24. Pregnancy, lactation, or breastfeeding
  25. Known that are untreated, symptomatic, or require therapy to control symptoms

    • Patients with a history of adequately treated brain metastases are eligible. Adequately treated brain metastases are defined as those having no ongoing requirement for medical therapy to control symptoms, and no evidence of progression or hemorrhage for ≥ 2 months after radiation treatment (such as whole brain radiotherapy or radiosurgery [Gamma Knife, linear accelerator, or equivalent]) and/or ≥ 3 months after surgical treatment, as ascertained by clinical examination and brain imaging (magnetic resonance imaging [MRI] or CT scan) during the screening period. Any medical therapy for brain metastases (e.g., steroids or seizure medications) must have been discontinued without the subsequent appearance of symptoms for ≥ 4 weeks before the first dose of study-drug treatment in Cycle 1.
  26. Inability to comply with study and follow-up procedures
  27. No other history of or ongoing that would potentially interfere with the interpretation of the pharmacodynamics (PD) or efficacy assays
  28. Need to take a concomitant medication, dietary supplement, or food that is prohibited during the study
  29. History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan (History of radiation pneumonitis in the radiation field (fibrosis) is permitted).
Terms in these criteria, in plain language(34)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
148 participants (actual)

Study arms

  • Experimental
    Stage 1

    Dose-escalation

    Drug: HM95573, cobimetinib

  • Experimental
    Stage 1b

    Dose-escalation

    Drug: HM95573, cetuximab

  • Experimental
    Stage 2 (Cohort I and II)

    Dose-expansion

    Drug: HM95573, cobimetinib

  • Experimental
    Stage 2 (Cohort III)

    Dose-expansion

    Drug: HM95573, cetuximab

Interventions

  • DrugHM95573, cobimetinib

    Drug pages: Belvarafenib · Cobimetinib

    Regimen: twice daily (BID), continuous dosing for HM95573, once daily (QD) 21 days, 7 days off for cobimetinib

  • DrugHM95573, cetuximab

    Drug pages: Belvarafenib · Cetuximab

    Regimen: twice daily (BID), continuous dosing for HM95573

  • DrugHM95573, cobimetinib

    Drug pages: Belvarafenib · Cobimetinib

    Regimen: Recommended dose (RD) and schedule selected based on the data of safety, tolerability, pharmacokinetics, and anti-tumor activity tested in Stage 1

  • DrugHM95573, cetuximab

    Drug pages: Belvarafenib · Cetuximab

    Regimen: Expansion dose of HM95573 selected based on the data of safety and tolerability tested in Stage 1b

06

What researchers measure

Primary outcomes

  1. Percentage of patients with Adverse Events, Serious Adverse Events, and Adverse Events of Special Interest as assessed by CTCAE v4.03

    Time frame: up to approximately 3 years

  2. Number of patients with DLTs

    Time frame: 28 days

  3. MTDs of HM95573 and cobimetinib, or HM95573 and cetuximab

    Time frame: End of Stage 1, an approximately 2 years

  4. Recommended Phase II dose (RPIID) of HM95573 and cobimetinib, or HM95573 and cetuximab

    Time frame: End of Stage 1, an approximately 2 years

Secondary outcomes

  1. Area Under the Concentration-Time Curve (AUC) of HM95573 and cobimetinib, or HM95573 and cetuximab

    Time frame: Cycle1 Day1, Cycle1 Day15, Cycle1 Day21, Cycle2 Day1, Cycle3 Day1, Study completion, an approximately 2 years

  2. Maximum Serum Concentration (Cmax) of HM95573 and cobimetinib, or HM95573 and cetuximab

    Time frame: Cycle1 Day1, Cycle1 Day15, Cycle1 Day21, Cycle2 Day1, Cycle3 Day1, Study completion, an approximately 2 years

  3. Time to maximum concentration (Tmax) of HM95573 and cobimetinib, or HM95573 and cetuximab

    Time frame: Cycle1 Day1, Cycle1 Day15, Cycle1 Day21, Cycle2 Day1, Cycle3 Day1, Study completion, an approximately 2 years

  4. FDG-PET and molecular biomarkers assessed in pre- and post-treatment tumor tissues

    Time frame: Screening, Cycle1 Day15

  5. Preliminary assessment of the antitumor activity of HM95573 and cobimetinib, or HM95573 and cetuximab measured by RECIST v1.1.

    Time frame: Screening, During Days 22-28 (Day 25 ± 3 days) in Cycle 2 and 4, and then every 8 weeks (±7 days), until disease progression, assessed approximately 3 years

07

Study locations

9 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2017 (actual). Primary completion is estimated for Sep 2024, 88 months after the start.

Of 286 industry-sponsored phase 1 interventional studies under Neoplasm Metastasis, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 75. This study's planned 88 months is above that.

Counting every sponsor, half of 496 studies reached it within 54 months; a quarter within 33 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2017
First posted
Sep 15, 2017
StartActual
May 22, 2017
Primary completionEst.
Sep 30, 2024
CompletionEst.
Dec 31, 2024
Last update
Aug 1, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 1, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03284502
Responsible party
Sponsor
First posted
Sep 15, 2017
Start date
May 22, 2017
Primary completion
Sep 30, 2024 (estimated)
Completion
Dec 31, 2024 (estimated)
Last update
Aug 1, 2023

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Belvarafenib · Cobimetinib · Cetuximab

Start the discussion